期刊文献+

单克隆抗体CH12抑制头颈部鳞状细胞癌裸鼠种植瘤的生长 被引量:1

CH12 monoclonal antibody inhibits growth of head and neck squamous cell carcinomas xenografts in nude mice
下载PDF
导出
摘要 目的:观察嵌合型单克隆抗体CH12对头颈部鳞状细胞癌(head and neck squamous cell carcinomas,HNSCC)裸鼠种植瘤生长的抑制作用,为进一步研究CH12单抗在肿瘤治疗中的作用提供参考数据。方法:Western blotting检测5种HNSCC细胞系A253、CAL27、Detroit 562、FaDu和RPMI 2650中表皮生长因子受体(epidermal growth factor receptor,EGFR)的表达,流式细胞术检测CH12单抗同这5种细胞系的结合能力。皮下接种CAL27和A253细胞,建立HNSCC裸鼠种植瘤模型。模型鼠腹腔注射CH12单抗,以PBS作为阴性对照,观察肿瘤生长情况,绘制肿瘤生长曲线。结果:EGFR在CAL27、A253、FaDu及Detroit 562细胞中均有不同程度的表达,其中CAL27细胞中EGFR的表达水平最高,A253细胞次之。CH12单抗与5种HNSCC细胞系的结合能力由高到低依次为CAL27、FaDu、A253、Detroit 562和RPMI 265细胞。CH12单抗对CAL27和A253细胞裸鼠种植瘤的生长均有显著抑制作用,抑瘤率分别为56.8%(P=0.022)和59.7%(P=0.015)。结论:单克隆抗体CH12对EGFR高表达的HNSCC细胞种植瘤的生长具有明显的抑制作用。 Objective: To investigate the inhibitory effect of chimeric monoclonal antibody CH12 on the growth of head and neck squamous cell carcinoma(HNSCC) xenografts in vivo,and to provide basis for further study on the effect CH12 antibody on tumor therapy.Methods: The protein expression levels of the epidermal growth factor receptor(EGFR) in A253,CAL27,Detroit 562,FaDu and RPMI 2650 HNSCC cell lines were analyzed by Western blotting.The binding capacity of CH12 antibody with these five cell lines was detected by flow cytometry.CAL27 and A253 cells were subcutaneously inoculated into nude mice to establish HNSCC xenograft models.The mice with xenografted tumor were randomized into two groups: a vehicle control group(PBS) and a treatment group(CH12).Tumor volume was recorded at a regular time interval,and then the tumor growth curve was drawn.Results: EGFR was expressed in CAL27,A253,FaDu and Detroit 562 cell lines,with the highest expression in CAL27 cells and the second highest expression in A253 cells.The binding affinity of CH12 with five cell lines was followed by CAL27,FaDu,A253,Detroit 562 and RPMI 265.CH12 significantly inhibited the tumor growth in both CAL27 and A253 xenografts compared with that in the control group,and the tumor growth inhibition ratios were 56.8%(P = 0.022) and 59.7%(P = 0.015) respectively.Conclusion: CH12 antibody can effectively inhibit the tumor growth of EGFR high-expressed HNSCC xenografts in vivo.
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 北大核心 2012年第3期276-279,共4页 Chinese Journal of Cancer Biotherapy
基金 上海市科委生物医药重点科技攻关项目资助(No.10431903700) 教育部高等学校博士学科点专项科研基金资助(No.20090073120109)~~
关键词 CH12 单克隆抗体 表皮生长因子受体 头颈部鳞状细胞癌 CH12 monoclonal antibody epidermal growth factor receptor(EGFR) head and neck squamous cell carcinoma(HNSCC)
  • 相关文献

参考文献20

  • 1Ciardiello F, Tortora G. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor [ J]. Clin Cancer Res, 2001, 7(10): 2958-2970.
  • 2Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment [ J ]. J Natl Cancer Inst, 2003, 95(12) : 851-867.
  • 3Ciardiello F, Tortora G. EGFR antagonists in cancer treatment [J]. N Engl J Med, 2008, 358(11): 1160-1174.
  • 4Schuler P, Boeckers P, Engers R, et al. EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma [J]. J Transl Med, 2006, 9: 168.
  • 5Kuan CT, Wikstrand C J, Bigner DD. EGF mutant receptor v m as a molecular target in cancer therapy [ J]. Endocr Relat Cancer, 2001, 8(2): 83-96.
  • 6Wang H, Jiang H, Zhou M, et al. Epidermal growth factor recep- tor v m enhances tumorigenicity and resistance to 5-fluorouracil in human hepatocellular carcinoma [ J ]. Cancer Lett, 2009, 279 (1) : 30-38.
  • 7Jiang H, Wang H, Tan Z, et al. Growth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant m ~J~ J Biol Chem, 2011, 286(7) : 5913-5920.
  • 8Wang H, Shi B, Zhang Q, et al. Growth and metastasis suppres- sion of glioma xenografts expressing exon 4-deletion variant of epi- dermal growth factor receptor by monoclonal antibody CH12-medi- ated receptor degradation [J]. Faseb J, 2011, 26(1): 73-80.
  • 9Wang H, Zhou M, Shi B, et al. Identification of an exon 4-dele- tion variant of epidermal growth factor receptor with increased me- tastasis-promoting capacity i J ~. Neoplasia, 2011, 13 ( 5 ) : 461- 471.
  • 10Garrett TP, Burgess AW, Gan HK, et al. Antibodies specifically targeting a locally misfolded region of tumor associated EGFR [ J]. Proc Natl Acad Sci U S A, 2009, 106(13) : 5082-5087.

同被引文献24

  • 1JEMAL A, SIEGEL R, WAPD E. Cancer statistics, 2009 [ J]. CA Cancer J Clin, 2009, 59(4) : 225 -249.
  • 2CIARDIELLO F G, TORTORA. EGFR antagonists in cancer treat- ment[J]. N Engl J ned, 2008, 358(11) : 1160 -1174.
  • 3MOON C Y K, CHAE, J LEE. Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab [J]. Exp Biol Med (Maywood), 2010, 235(8) : 907 -920.
  • 4BONNER J A, HARAR P M, GIRALT J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5 - year survival data from a phase 3 randornised trial, and relation between cetuximab -induced rash and survival[ J]. Lancet Oncol, 2010, 11(1) : 21 -25.
  • 5VERMORKEN J B, MESIA R, RIVELA E, et al. Platinum- based chemotherapy plus cetuximab in head and neck cancer[ J]. N Engl J Med, 2008, 359(11) : 1116 -1127.
  • 6SPECENIER P, VER MORKEN J B. Vermorken, cetuximab in the treatment of squamous cell carcinoma of the head and neck [J].Expert Rev Anticancer Ther, 2011, 11 (4) : 511 - 524.
  • 7RAMAKRISHNAN M S, ESWARAIAH A, CROMBET T, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin[ J]. MAbs, 2009, 1 ( 1 ) : 41 -48.
  • 8RODRIGUEZ M O. Nimotuzumab plus radiotherapy for unresec-ta- ble squamous - cell carcinoma of the head and neck [ J ]. Cancer Biol Ther, 2010, 9(5) : 343 -349.
  • 9FENG F Y, VARAMBALLY S, TOMLINS S A, et al. Role of epi- derma[ growth factor receptor degradation in gemcitabine - media- ted cytotoxicity[ J ]. Oncogene, 2007, 26 (23) : 3431 - 3439.
  • 10CAPONIGRO F, ROMANO C, MILANO A, et al. A phase trial of gefitinib and radiotherapy in patients with locally advanced inopera- ble squamous cell carcinoma of the head and neck [ J ]. Anticancer Drugs, 2008, 19(7) : 739 -744.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部